BIOBASE today announced a new agreement with the University of Southern California and The Children’s Hospital of Philadelphia. The agreement covers the exclusive worldwide marketing and distribution of the ANNOVAR tool to commercial users. ANNOVAR enables the annotation of genomic variants on a variety of species including human. It is an efficient software tool for rapidly screening and annotating genetic variants detected from next-generation sequencing results on a genome-wide level.
ANNOVAR will be distributed stand alone, and as a complement to Genome Trax™, a database of diseases, phenotypes and functional effects of genomic variants assembled from published results by qualified experts.
“ANNOVAR is one of the most widely accepted software packages in the Next Generation Sequencing community” said Frank Schacherer, CTO at BIOBASE. “This flexible tool is ideally suited for everyone who needs to build annotation pipelines, and perfectly complements our unique annotation data. For our users, this will mean drilling down to relevant results, faster.”
“By integrating the annotation functionality of ANNOVAR with the wealth of annotation databases provided by BIOBASE, users could be getting a boost on their ability to mine functional information from genome variants and accelerate biomedical discoveries” stated Kai Wang, the developer of ANNOVAR and an Assistant Professor at the University of Southern California.